Pfizer Inc. $PFE Stock: Summit Global Investments Increases Holdings

Summit Global Investments grew its position in Pfizer Inc. (NYSE:PFE) by 27.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 76,933 shares of the biopharmaceutical company’s stock after acquiring an additional 16,416 shares during the period. Summit Global Investments’ holdings in Pfizer were worth $2,194,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Retirement Wealth Solutions LLC grew its position in Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 509 shares during the last quarter. Keb Asset Management LLC bought a new position in Pfizer in the second quarter valued at about $26,000. Field & Main Bank bought a new position in Pfizer in the second quarter valued at about $27,000. Evolution Wealth Management Inc. boosted its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Bullseye Investment Management LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Pfizer Trading Up 1.8%

Shares of PFE stock opened at $30.48 on Friday. The stock has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.07 and a beta of 0.32. The stock has a 50-day moving average of $28.55 and a 200-day moving average of $26.79. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $30.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $0.78 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.6%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Finally, Scotiabank upped their price target on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.65.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.